Odyssey Therapeutics, Inc. (ODTX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$16.94

From 52W high−37.07%

Volume300470.00

Market cap$869.86M

P/E (TTM)—

P/S (TTM)292.3x

Div yield—

Key dataOct 19, 2026

Open

$16.94

From 52W high

−37.07%

Volume

300470.00

Market cap

$869.86M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.0x

P/E (TTM)

—

RSI (14)

40.2

MomentumView details →

1D Return

+5.42%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.0x

EV/Sales

196.3x

P/S (TTM)

292.3x

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−4994.86%

EBITDA Margin

−4860.42%

ROE (TTM)

−35.29%

ROA (TTM)

−30.72%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+5.42%

YTD Return

—

1Y Return

—

RSI (14)

40.2

vs 50D SMA

−20.05%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

11.36x

Quick Ratio

11.36x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$6.77

EPS Surprise

−508.00%

Beats (12Q)

0/12

Next Q EPS Est

−$1.10

Avg Surprise (4Q)

−508.00%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsNov 4, 2026 →

Latest newsMore news →

Odyssey Therapeutics announced that additional results from the OD-001 induction period of its Phase 2a trial in moderate to severe ulcerative colitis will be featured in an oral presentation at UEG Week 2026 in Barcelona, Spain, on October 17-20, 2026.14d ago

Evotec SE announced a strategic R&D collaboration with Odyssey Therapeutics to discover new treatments for autoimmune and inflammatory diseases using Evotec's AI-enabled discovery platform.75d ago

Similar companies

Rigel Pharmaceuticals, Inc.RIGL Jade Biosciences, Inc.JBIO SL Science Holding Limited Ordinary SharesSLBT Theravance Biopharma, Inc.TBPH ArriVent BioPharma, Inc. Common StockAVBP CANbridge Pharmaceuticals Inc.01228.HK Find similar companies →

Latest newsMore news →

Odyssey Therapeutics announced that additional results from the OD-001 induction period of its Phase 2a trial in moderate to severe ulcerative colitis will be featured in an oral presentation at UEG Week 2026 in Barcelona, Spain, on October 17-20, 2026.14d ago Evotec SE announced a strategic R&D collaboration with Odyssey Therapeutics to discover new treatments for autoimmune and inflammatory diseases using Evotec's AI-enabled discovery platform.75d ago